Adherence to Therapy in Chronic Obstructive Pulmonary Disease: A Systematic Review

Świątoniowska, Natalia; Chabowski, Mariusz; Polański, Jacek; Mazur, Grzegorz; Jankowska‐Polańska, Beata

doi:10.1007/5584_2019_477

Cited by 17 publications

(17 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While self-reporting of treatment compliance could introduce recall bias by either over-reporting or under-reporting depending on patient’s behavior in the recent past. 22 To date, there is no “gold standard” self-report questionnaire to assess treatment adherence in COPD patients.…”

Section: Introductionmentioning

confidence: 99%

Adherence to Inhaled Therapy in Patients with COPD Associated to Pneumoconiosis

Peng¹,

Duan²,

Li³

et al. 2021

COPD

View full text Add to dashboard Cite

Background Pneumoconiosis has high prevalence of chronic obstructive pulmonary disease (COPD), respiratory morbidity, and mortality. Objective The aim of the present study was to examine patient characteristics and adherence to inhaled therapy among pneumoconiosis with COPD in a real-world clinical setting. Methods A cohort of pneumoconiosis patients with COPD prescript with at least one type of long-acting inhaled drug was followed for adherence for 2 years. Demographic and COPD-related characteristics were collected in baseline. Results In baseline, after adjusting for age, dust exposure duration positively correlated with number of acute exacerbation (AE) frequency in the last year. There were close associations among COPD Assessment Tool (CAT) score, modified Medical Research Council Dyspnea Scale (mMRC) grade, number of AE, and pre-FEV 1 value. Of 296 participants originally recruited, 213 participants finished the 2-year follow-up for adherence. 122 (57.28%) were non-adherent to inhaled therapy. The most common reason for non-adherence was “relief of symptoms after short-term controller medication use” (53.28%). Patients who were non-adherent reported higher body mass index (BMI), less AE events in the last year, higher pre-FEV 1 value, higher post-FEV 1 value and low CAT, mMRC scores compared to adherent in baseline. High pre-FEV 1 value (OR = 1.04, CI = 1.018–1.064) and low mMRC scores (OR = 0.406, CI = 0.214–0.771) were risk factors found associated with non-adherence. Conclusion A majority of pneumoconiosis patients complicated with COPD have suboptimal inhaled therapy adherence. Evidence-based, adherence-enhancing interventions should be targeted on less severe subjects.

show abstract

Section: Introductionmentioning

confidence: 99%

Adherence to Inhaled Therapy in Patients with COPD Associated to Pneumoconiosis

Peng¹,

Duan²,

Li³

et al. 2021

COPD

View full text Add to dashboard Cite

show abstract

“… 14 Non-adherence to the guideline may be associated with a worse outcome than guideline adherence. 14 , 16–18 However, this kind of scenario might be different in the present study, in which low-cost dual therapy could be more effective than monotherapy for COPD patients with low disease activity. This kind of management was supposed to be associated with a better outcome of COPD patients; however, further study is needed to clarify this issue.…”

Section: Discussionmentioning

confidence: 69%

The Impact of the Pay-for-Performance Program on the Outcome of COPD Patients in Taiwan After One Year

Cheng¹,

Lai²,

Wang³

et al. 2022

COPD

View full text Add to dashboard Cite

Objective To investigate the impact of a multidisciplinary intervention on the clinical outcomes of patients with COPD. Methods This study retrospectively extracted the data of patients enrolled in the national pay-for-performance (P4P) program for COPD in four hospitals. Only COPD patients who received regular follow-up for at least one year in the P4P program between September 2018 and December 2020 were included. Results A total of 1081 patients were included in this study. Among them, 424 (39.2%), 287 (26.5%), 179 (16.6%), and 191 (17.7%) patients were classified as COPD Groups A, B, C, and D, respectively. Dual therapy with long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) was the most used inhaled bronchodilator at baseline (n = 477, 44.1%) patients, followed by LAMA monotherapy (n = 195, 18.0%), triple therapy with inhaled corticosteroid (ICS)/LABA/LAMA (n = 184, 17.0%), and ICS/LABA combination (n = 165, 15.3%). After one year of intervention, 374 (34.6%) and 323 (29.9%) patients had their pre- and post-bronchodilator-forced expiratory volume in one second (FEV1) increase of more than 100 mL. Both the COPD Assessment Test (CAT) and modified British Medical Research Council (mMRC) scores had a mean change of −2.2 ± 5.5 and −0.3 ± 0.9, respectively. The improvement in pulmonary function and symptom score were observed across four groups. The decreased number of exacerbations was only observed in Groups C and D, and not in Groups A and B. Conclusion This real-world study demonstrated that the intervention in the P4P program could help improve the clinical outcome of COPD patients. It also showed us a different view on the use of dual therapy, which has a lower cost in Taiwan.

show abstract

“…The patient is the centre of interest of healthcare providers to whom optimization of treatment outcomes is the ultimate goal 1,2 . Patients' non‐adherence to drug therapy, as defined by WHO, 3 has been recognized as a significant culprit of treatment failure in 50%–60% of those suffering from non‐communicable diseases, especially those with chronic diseases.…”

Section: What Is Known and Objectivesmentioning

confidence: 99%

Test performance of self‐report adherence tools in patients with hypertension: A systematic review and a meta‐analysis

Al‐Alaili

Abdi

Başgut

2022

Clinical Pharmacy Therapeu

View full text Add to dashboard Cite

What Is Known and Objectives: Adherence has proved to have a positive influence on achieving plausible treatment outcomes. Self-report questionnaires are widely used in evaluating adherence, creating thus a high-powered research field. This review aims to provide an update of scales used in hypertension, which are compared and analysed against reliability and validity.Methods: PubMed, Web of Science and Cochrane Library were searched in May 2022 to identify studies. We extracted the study characteristics and evaluated their quality. A random-effects model with subgroup analysis was used to calculate estimates and heterogeneity parameters as well as regressions, funnel and forest plots. A bivariate model was selected to conduct validity analyses and draw receiver operating characteristic (ROC) curves.Results and Discussion: Fifty-five articles were identified and classified into 22 different reliable and validated tools. Pooled analyses predicted an overall good Cronbach's alpha of 0.76 (95%CI:0.67-0.83), a good ICC of 0.8 (95%CI:0.72-0.86) and an excellent correlation coefficient of 0.91 (95%CI:0.86-0.95), which all showed high heterogeneity and slight detection of asymmetry. Regression analyses showed that only

show abstract

Adherence to Therapy in Chronic Obstructive Pulmonary Disease: A Systematic Review

Cited by 17 publications

References 34 publications

Adherence to Inhaled Therapy in Patients with COPD Associated to Pneumoconiosis

Adherence to Inhaled Therapy in Patients with COPD Associated to Pneumoconiosis

The Impact of the Pay-for-Performance Program on the Outcome of COPD Patients in Taiwan After One Year

Test performance of self‐report adherence tools in patients with hypertension: A systematic review and a meta‐analysis

Contact Info

Product

Resources

About